Lemtrada (alemtuzumab) - Important Safety Information from Sanofi Genzyme as approved by the HPRA

Notice type: 3rd Party Publications

Date: 24/04/2019

 

Problem Or Issue:

Important Safety Information communication from Sanofi Genzyme on Lemtrada (alemtuzumab): Restriction of use due to serious safety concerns

 

Important Safety Information - Lemtrada (alemtuzumab)

 

 



« Back